Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.82 USD | +4.09% | +1.60% | +25.30% |
May. 03 | Aileron Therapeutics Closes Direct Offering of Shares, Warrants | MT |
May. 01 | Transcript : Aileron Therapeutics, Inc. - Special Call |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 64.83M |
---|---|---|---|---|---|
Net income 2024 * | -23M | Net income 2025 * | -27M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.06
x | P/E ratio 2025 * |
-2.11
x | Employees | 15 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.91% |
Latest transcript on Aileron Therapeutics, Inc.
1 day | +4.09% | ||
1 week | +1.60% | ||
Current month | -16.04% | ||
1 month | -34.25% | ||
3 months | -20.42% | ||
6 months | +114.61% | ||
Current year | +25.30% |
Managers | Title | Age | Since |
---|---|---|---|
Brian Windsor
CEO | Chief Executive Officer | 57 | 23-10-30 |
Director of Finance/CFO | 48 | 23-09-30 | |
David Annis
CTO | Chief Tech/Sci/R&D Officer | 51 | 07-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 68 | 19-06-18 | |
Alan Musso
BRD | Director/Board Member | 62 | 23-10-30 |
Brian Windsor
CEO | Chief Executive Officer | 57 | 23-10-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 3.82 | +4.09% | 59,933 |
24-05-09 | 3.67 | +0.55% | 125,113 |
24-05-08 | 3.65 | -1.08% | 44,507 |
24-05-07 | 3.69 | -6.58% | 241,733 |
24-05-06 | 3.95 | +5.05% | 87,757 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.30% | 64.83M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- ALRN Stock